Copyright
©The Author(s) 2017.
World J Gastrointest Endosc. Feb 16, 2017; 9(2): 61-69
Published online Feb 16, 2017. doi: 10.4253/wjge.v9.i2.61
Published online Feb 16, 2017. doi: 10.4253/wjge.v9.i2.61
Table 2 Association among indications and gastric intestinal metaplasia
Frequency in patients with gastric IM1 | Frequency in patients without gastric IM1 | Univariate analysis | Multivariate analysis | |
[OR (95%CI)] | ||||
Abdominal pain | 188 (41.7%) | 93 (54.4%) | P = 0.005 | 0.81 (0.55, 1.18), P = 0.267 |
Weight loss | 63 (13.5%) | 21 (7.4%) | P = 0.014 | 1.81 (0.95, 3.66), P = 0.073 |
GI bleed | 38 (8.4%) | 13 (7.6%) | P = 0.755 | 1.23 (0.63, 2.52), P = 0.558 |
Nausea | 60 (13.3%) | 27 (15.8%) | P = 0.426 | 0.97 (0.58, 1.65), P = 0.903 |
Dysphagia | 59 (13.1%) | 26 (15.2%) | P = 0.490 | 0.74 (0.44, 1.26), P = 0.259 |
Barrett’s esophagus | 10 (2.2%) | 8 (4.7%) | P = 0.123 | 0.32 (0.12, 0.92), P = 0.034 |
- Citation: Gomez JM, Patrie JT, Bleibel W, Frye JW, Sauer BG, Shami VM, Stelow EB, Moskaluk CA, Wang AY. Gastric intestinal metaplasia is associated with gastric dysplasia but is inversely correlated with esophageal dysplasia. World J Gastrointest Endosc 2017; 9(2): 61-69
- URL: https://www.wjgnet.com/1948-5190/full/v9/i2/61.htm
- DOI: https://dx.doi.org/10.4253/wjge.v9.i2.61